TITLE

Botulinum toxin: Cost-effective for urge incontinence

AUTHOR(S)
Guttman, Cheryl
PUB. DATE
December 2008
SOURCE
Urology Times;12/1/2008, Vol. 36 Issue 15, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the data presented by researchers from Duke University which reveals the cost-effectiveness of Botulinum toxin (Botox) for urge incontinence treatment. The data, which utilized a Markov decision analysis model, shows that Botox is a cost effective strategy for the idiopathic urge incontinence management and medication. In addition, the said treatment has been approved by Food and Drug Administration (FDA) for urge incontinence.
ACCESSION #
35950907

 

Related Articles

  • Botox OK for incontinence. Gustafson, Mary // McKnight's Long-Term Care News;Oct2011, Vol. 32 Issue 10, p3 

    The article reports on the approval of Botox (botulinum toxin type A) by the U.S. Food and Drug Administration (FDA) for treating incontinence in patients with neurologic conditions including spinal cord injury and overactive bladder.

  • Botulinum toxin A considered good value for money.  // PharmacoEconomics & Outcomes News;5/15/2010, Issue 603, p6 

    The article presents a study which indicates that botulinum toxin A may be cost effective in urinary incontinence treatment due to detrusor activity found in patients with multiple sclerosis.

  • Botox best for urge incontinence?  // PharmacoEconomics & Outcomes News;9/21/2013, Issue 687, p6 

    The article discusses a study on the cost effectiveness of botulinum toxin A (Botox) for the treatment of women with urinary incontinence, presented at the Annual Meeting of the International Continence Society held in Barcelona, Spain on August 26-30, 2013.

  • BOTOX for bladder control. LOTEMPIO, SUSAN M. // New Mobility;Oct2013, Vol. 24 Issue 241, p14 

    The article offers the author's insight on her experience of Botox injections to regain control of her bladder. She relates her experience of work-related stress due to urinary incontinence and its impact on the quality of her life and those who have the disorder. She discusses how the Botox...

  • Botulinum toxin A cost effective for urinary incontinence in France….  // PharmacoEconomics & Outcomes News;9/18/2010, Issue 612, p5 

    The article discusses two studies on the cost effectiveness of Botulinum toxin A for patients with urinary incontinence in France and Great Britain, presented at the joint annual meeting of the International Continence Society and the International UroGynecological Association (ICA/IUGA) in...

  • Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective. Hamid, Rizwan; Loveman, Clara; Millen, Jim; Globe, Denise; Corbell, Catherine; Colayco, Danielle; Stanisic, Sanja; Gultyaev, Dmitry // PharmacoEconomics;Apr2015, Vol. 33 Issue 4, p381 

    Objectives: To evaluate the cost effectiveness of onabotulinumtoxinA (BOTOX, 200 units [200 U]) for the management of urinary incontinence (UI) in adults with neurogenic detrusor overactivity (NDO) due to subcervical spinal cord injury or multiple sclerosis that is not adequately managed with...

  • ALLERGAN'S BOTOX GETS FDA APPROVAL FOR CERVICAL DYSTONIA.  // Biotech Business;Feb2001, Vol. 14 Issue 2, p2 

    Deals with the approval of the United States Food and Drug Administration on the use of Botulinum Toxin Type A (BOTOX) Purified Neurotoxin Complex of Allergan Inc. for the treatment of adults with cervical dystonia.

  • FDA warns of illegal Botox from foreign suppliers.  // Reactions Weekly;1/12/2013, Issue 1434, p3 

    The article reports on the warning issued by the U.S. Food and Drug Administration (FDA) to medical practices that they may have received unapproved versions of Botox from foreign suppliers owned and operated by Canada drugs.

  • Incontinence patch goes over-the-counter.  // FDA Consumer;Jul/Aug98, Vol. 32 Issue 4, p5 

    Reports on the approval of the over-the-counter sale of `UroMed Patch' by the United States Food and Drug Administration. Use of this patch to help women reduce leakage from stress urinary incontinence; Amount of Americans affected by urinary incontinence; Information on the patch manufactured...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics